A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.
Farshid Dayyani, MD, PhD
Advertisement
Articles by Farshid Dayyani, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
2
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
3
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
4
Exa-Cel Improved HRQOL for in Transfusion-Dependent β-Thalassemia
5
